Market revenue in 2023 | USD 15.7 million |
Market revenue in 2030 | USD 42.7 million |
Growth rate | 15.3% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 45.22% in 2023. Horizon Databook has segmented the Thailand hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
In Thailand, the hereditary angioedema therapeutics market is mostly saturated with foreign players and their subsidiaries. HAE is a rare and potentially fatal genetic disorder, the rising prevalence of the condition, propels the need to prevent mortality and treat acute attacks, further fueling need for effective medications.
However, Thailand has not specified medication for treatment or prophylaxis. As a result, effective universal health coverage strategies for the management of HAE patients remain a challenge in Thailand.
However, the country encourages local generics manufacturers to develop and manufacture drugs. Furthermore, a number of strategic initiatives are undertaken in the country to enhance access to effective therapeutics.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Thailand hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account